PDL BioPharma, Inc. Message Board

and categorizes the stock as speculative. Shorts definetly don't want this puppy on the new high list. Some consolidation at current levels is to be expected. Just look at the trend lines (SMA's)-nice and steady, not too choppy. The divy's ex-date is only two weeks away...that should buoy the stock on any new market weakness (SAC, IRS, budget deficit, Syria, etc., etc.).

I told you guys this stock would hit the skids!! Down.06..Where are you guys from? Ohio? This dog will see $5 before it sees $7 errr $8 errrr I mean $9. Want me to spell it out for you Followtheidiot? S H O R T...If you were not sitting around a trailer watching House you could make money. Then you could by more pocket protectors. TOOLS!!

Sentiment: Hold

news coming?

terrific ER and growth, 10% dividend .

rare in the market.

As of March 31, PDLI's balance sheet reflected approximately $300M in cash, restricted cash, short term investments, and short and long term note receivables. On the other side of the ledger, PDLI has $313M of convertible notes outstandings, due in 2015. So there is not any net cash value from the balance sheet. They just completed a quarter where they did $54M in cashflow from operations. Assuming 13 additional quarters until the expiration of Queen Royalty payments (June 2016), there would be $700M in future cashflows (13 x 54M), plus let's say another $100M to reflect growth between now and 2016. So that's basically an expectation of $800M of cashflow between now and June 2016 or $5.71/share. That doesn't even take into account any discounting. Intangible factors which could add to that include a successful settlement of the lawsuit or the approval of a new drug and successful marketing which leads to additional royalties beyond the 2016 date (both factors that in my opinion really can't be counted on). The current valuation of the company is $1.15B! Are buyers just buying for the handsome dividend and yield, do they realize that there is a cliff out there on the not too distant horizon. As each quarter passes by, what should be happening is the stock price going down to reflect the payout and the shortening window until patent expiration. Not the opposite. When this market cools off, look out below.

Not nary a word from the boy. He must be checkin' his posum traps behind his outhouse.
Could be the late night shift at Sonic has him still sacked out. The same way PDLI has him
sacked out.
C'mon stooge....just a little comment.

I'm revising my short term forecast (5-week) to reflect the possibility of PDLI reaching a new 52 week high. I don't know what the catalyst, if any, will be. I saw that the short position increased by almost a million shares to over 22 million shares in the latest reporting period ended April 30. That's unbeleivable in this bull market, and it could be the only reason for a potential run to higher levels. Avinger definitely lit a fuse; now let's watch her blow! See you guys next week. LOL

So unlike you I have no problem posting on an up day. Congratulations on your 5% gain today and now being over $8/share.

I think Starcushing brought up some excellent points which you might have somebody read and explain to you since both of those tasks are well beyond your capability.

I bought PDLI at $5-$6/share 3 years ago, made alot of money in the stock, but after doing my own analysis of future cashflows decided to exit the position around $8/share. A few years ago, I believed the remaining cashflows justified a $7-$8/share valuation. Now with only 3 years remaining on the Queen royalties, even with the additional cashflows generated by their latest investments, some of which may carry beyond 2016, I don't think the current valuation is justified. I would have rather have seen them return more of the money to the shareholders through a special dividend or by increasing the dividend the remaining three years. Instead, IMO, they are racheting up the risk scale by investing shareholders cash in riskier ventures, unrated debt, etc. to try and obtain higher returns on cash to try and keep it a going concern beyond the royalty expiration date. I had a difficult time getting to the current valuation after discounting back future anticipated cashflows and royalties.